147 related articles for article (PubMed ID: 35703345)
1. Dual STAT‑3 and IL‑6R inhibition with stattic and tocilizumab decreases migration, invasion and proliferation of prostate cancer cells by targeting the IL‑6/IL‑6R/STAT‑3 axis.
Méndez-Clemente A; Bravo-Cuellar A; González-Ochoa S; Santiago-Mercado M; Palafox-Mariscal L; Jave-Suárez L; Solorzano-Ibarra F; Villaseñor-García M; Ortiz-Lazareno P; Hernández-Flores G
Oncol Rep; 2022 Aug; 48(2):. PubMed ID: 35703345
[TBL] [Abstract][Full Text] [Related]
2. Combination Blockade of the IL6R/STAT-3 Axis with TIGIT and Its Impact on the Functional Activity of NK Cells against Prostate Cancer Cells.
González-Ochoa S; Tellez-Bañuelos MC; Méndez-Clemente AS; Bravo-Cuellar A; Hernández Flores G; Palafox-Mariscal LA; Haramati J; Pedraza-Brindis EJ; Sánchez-Reyes K; Ortiz-Lazareno PC
J Immunol Res; 2022; 2022():1810804. PubMed ID: 35465350
[TBL] [Abstract][Full Text] [Related]
3. Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3-AR axis inhibition.
Liu C; Lou W; Armstrong C; Zhu Y; Evans CP; Gao AC
Prostate; 2015 Sep; 75(13):1341-53. PubMed ID: 25970160
[TBL] [Abstract][Full Text] [Related]
4. Tocilizumab suppresses the pro-carcinogenic effects of breast cancer-associated fibroblasts through inhibition of the STAT3/AUF1 pathway.
Al-Jomah N; Al-Mohanna FH; Aboussekhra A
Carcinogenesis; 2021 Dec; 42(12):1439-1448. PubMed ID: 34718441
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling.
Wang W; Wang L; Mizokami A; Shi J; Zou C; Dai J; Keller ET; Lu Y; Zhang J
Chin J Cancer; 2017 Mar; 36(1):35. PubMed ID: 28356132
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of STAT3 signaling targets both tumor-initiating and differentiated cell populations in prostate cancer.
Han Z; Wang X; Ma L; Chen L; Xiao M; Huang L; Cao Y; Bai J; Ma D; Zhou J; Hong Z
Oncotarget; 2014 Sep; 5(18):8416-28. PubMed ID: 25261365
[TBL] [Abstract][Full Text] [Related]
7. Resistance to Anti-VEGF Therapy Mediated by Autocrine IL6/STAT3 Signaling and Overcome by IL6 Blockade.
Eichten A; Su J; Adler AP; Zhang L; Ioffe E; Parveen AA; Yancopoulos GD; Rudge J; Lowy I; Lin HC; MacDonald D; Daly C; Duan X; Thurston G
Cancer Res; 2016 Apr; 76(8):2327-39. PubMed ID: 26921327
[TBL] [Abstract][Full Text] [Related]
8. 27-Hydroxycholesterol Impairs Plasma Membrane Lipid Raft Signaling as Evidenced by Inhibition of IL6-JAK-STAT3 Signaling in Prostate Cancer Cells.
Dambal S; Alfaqih M; Sanders S; Maravilla E; Ramirez-Torres A; Galvan GC; Reis-Sobreiro M; Rotinen M; Driver LM; Behrove MS; Talisman TJ; Yoon J; You S; Turkson J; Chi JT; Freeman MR; Macias E; Freedland SJ
Mol Cancer Res; 2020 May; 18(5):671-684. PubMed ID: 32019810
[TBL] [Abstract][Full Text] [Related]
9. Chikusetsusaponin IVa Butyl Ester (CS-IVa-Be), a Novel IL6R Antagonist, Inhibits IL6/STAT3 Signaling Pathway and Induces Cancer Cell Apoptosis.
Yang J; Qian S; Cai X; Lu W; Hu C; Sun X; Yang Y; Yu Q; Gao SP; Cao P
Mol Cancer Ther; 2016 Jun; 15(6):1190-200. PubMed ID: 26929249
[TBL] [Abstract][Full Text] [Related]
10. The STAT3 Inhibitor Galiellalactone Effectively Reduces Tumor Growth and Metastatic Spread in an Orthotopic Xenograft Mouse Model of Prostate Cancer.
Canesin G; Evans-Axelsson S; Hellsten R; Sterner O; Krzyzanowska A; Andersson T; Bjartell A
Eur Urol; 2016 Mar; 69(3):400-4. PubMed ID: 26144873
[TBL] [Abstract][Full Text] [Related]
11. Anti-Tumor Effects of Astaxanthin by Inhibition of the Expression of STAT3 in Prostate Cancer.
Sun SQ; Zhao YX; Li SY; Qiang JW; Ji YZ
Mar Drugs; 2020 Aug; 18(8):. PubMed ID: 32784629
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Stat3 activation by sanguinarine suppresses prostate cancer cell growth and invasion.
Sun M; Liu C; Nadiminty N; Lou W; Zhu Y; Yang J; Evans CP; Zhou Q; Gao AC
Prostate; 2012 Jan; 72(1):82-9. PubMed ID: 21538419
[TBL] [Abstract][Full Text] [Related]
13. Brevilin A is a potent anti-metastatic CRC agent that targets the VEGF-IL6-STAT3 axis in the HSCs-CRC interplay.
Fan X; Meng M; Li B; Chen H; Tan J; Xu K; Xiao S; Kwan HY; Liu Z; Su T
J Transl Med; 2023 Apr; 21(1):260. PubMed ID: 37062842
[TBL] [Abstract][Full Text] [Related]
14. Periostin Mediates TGF-β-Induced Epithelial Mesenchymal Transition in Prostate Cancer Cells.
Hu Q; Tong S; Zhao X; Ding W; Gou Y; Xu K; Sun C; Xia G
Cell Physiol Biochem; 2015; 36(2):799-809. PubMed ID: 26021267
[TBL] [Abstract][Full Text] [Related]
15. miR-451 acts as a suppressor of angiogenesis in hepatocellular carcinoma by targeting the IL-6R-STAT3 pathway.
Liu X; Zhang A; Xiang J; Lv Y; Zhang X
Oncol Rep; 2016 Sep; 36(3):1385-92. PubMed ID: 27461244
[TBL] [Abstract][Full Text] [Related]
16. Effects of miR-200c on the migration and invasion abilities of human prostate cancer Du145 cells and the corresponding mechanism.
Shi R; Xiao H; Yang T; Chang L; Tian Y; Wu B; Xu H
Front Med; 2014 Dec; 8(4):456-63. PubMed ID: 25363395
[TBL] [Abstract][Full Text] [Related]
17. Nimbolide inhibits 2D and 3D prostate cancer cells migration, affects microtubules and angiogenesis and suppresses B-RAF/p.ERK-mediated in vivo tumor growth.
Mahmoud N; Dawood M; Huang Q; Ng JPL; Ren F; Wong VKW; Efferth T
Phytomedicine; 2022 Jan; 94():153826. PubMed ID: 34775358
[TBL] [Abstract][Full Text] [Related]
18. HDL and sphingosine-1-phosphate activate stat3 in prostate cancer DU145 cells via ERK1/2 and S1P receptors, and promote cell migration and invasion.
Sekine Y; Suzuki K; Remaley AT
Prostate; 2011 May; 71(7):690-9. PubMed ID: 20979115
[TBL] [Abstract][Full Text] [Related]
19. IL6-induced metastasis modulators p-STAT3, MMP-2 and MMP-9 are targets of 3,3'-diindolylmethane in ovarian cancer cells.
Zou M; Zhang X; Xu C
Cell Oncol (Dordr); 2016 Feb; 39(1):47-57. PubMed ID: 26510945
[TBL] [Abstract][Full Text] [Related]
20. ASC-J9
Lin W; Luo J; Sun Y; Lin C; Li G; Niu Y; Chang C
Cancer Lett; 2018 Jul; 425():21-30. PubMed ID: 29425687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
